1 t the participating centres were potentially
eligible.
2 erminal pro-B-type natriuretic peptide) were
eligible.
3 ost suspicious axillary lymph node (LN) were
eligible.
4 visit within 12 months were determined to be
eligible.
5 Examination within 1 year of pregnancy were
eligible.
6 ve patients from the SwissTAVI Registry were
eligible.
7 e doses of anti-parkinsonian medication were
eligible.
8 1 patient was excluded at this stage as not
eligible.
9 on medication assisted treatment (MAT) were
eligible.
10 rom birth to 22 years of age with AT/RT were
eligible.
11 Patients undergoing >=1 IRs were
eligible.
12 tay or costs in adult surgical patients were
eligible.
13 inimum 3 weeks before study initiation) were
eligible.
14 inversion recovery (DWI-FLAIR) mismatch were
eligible.
15 caregivers aged 18 years or older were also
eligible.
16 fatinib + cetuximab and 85 on afatinib) were
eligible.
17 ck, lung, lymphoma, or melanoma cancers were
eligible.
18 or from January 1 to December 31, 2016, were
eligible.
19 clinical practices across North America were
eligible.
20 e of a single pediatric ophthalmologist were
eligible.
21 426 men registered interest; 306 (72%) were
eligible.
22 9 publications, 11 investigations were found
eligible (
3,183 relatives of ICU patients).
23 Nine hundred and ninety-three patients were
eligible (
56% male; 44% female; median age 62 years), 35
24 treatment for AUD between 2013 and 2017 were
eligible (
77% men); age at admission was 47 years [inter
25 Forty-six of 79
eligible acute respiratory distress syndrome survivors (
26 Among 39,226
eligible admissions, de-escalation occurred in 14,138 (3
27 ised, open-label, phase 2 trial, we enrolled
eligible adults (aged >=18 years) and children (aged bet
28 greater efforts should be made to vaccinate
eligible adults 50 years of age and older.
29 We analyzed antiretroviral therapy (ART)-
eligible adults newly linking to care at 64 clinics in Z
30 Transplantation-
eligible adults with newly diagnosed multiple myeloma we
31 Eligible adults with oHCM and New York Heart Association
32 s who had a tracheostomy tube; patients were
eligible after weaning from mechanical ventilation.
33 Of 158 patients enrolled, 132 were
eligible and 128 underwent iPET, which was positive in 1
34 city residents aged six years or older were
eligible and 9,899,828 (92.9%) participated.
35 predicted among age-cohorts that were fully-
eligible and partly-eligible for 4CMenB, respectively.
36 care, including those newly diagnosed, were
eligible and ready for same-day initiation under the SLA
37 All
eligible and treated patients were included in the analy
38 f people living with CHB, treat 80% of those
eligible,
and reduce attributable deaths by 65% by the y
39 Eligible articles contrasted either anxious patients to
40 III at birth, and their healthy infants were
eligible as matched controls.
41 years [interquartile range 28-41]) were ART-
eligible at enrollment.
42 Patients were
eligible at first relapse or first designation of refrac
43 Among 5343
eligible babies in these facilities, we assessed outcome
44 Among 366 103 CR-
eligible beneficiaries, 89 327 (24.4%) participated in C
45 identified validation patients, who had been
eligible but not randomized during recruitment for the P
46 estimated to suffer FA among those who were
eligible but refused DBPCFC.
47 e treatment change was successful in >50% of
eligible candidates, with C-peptide >252 pmol/L emerging
48 ble, and therefore it is crucial to identify
eligible candidates.
49 e eligible for analysis, with 359 (0.28%) of
eligible cases reported as RMR.
50 ective cohort study was performed using ECLS-
eligible CDH Study Group registry patients born between
51 A total of 294 consecutive
eligible children aged 7 to 11 years with -0.75 D to -5.
52 giving an overall testing uptake among 6062
eligible children of 60.0%.
53 testing uptake in terms of the proportion of
eligible children tested.
54 Eligible children were randomised to dolutegravir in ODY
55 ls from two birth cohorts; the first vaccine-
eligible cohort in Norway and a pre-vaccination cohort.
56 31.6% (95% CI, 30.3-32.9) for the PIONEER-HF
eligible cohort, and 32.2% (95% CI, 31.4-33.0) for the a
57 32.6% (95% CI, 31.3-33.9) for the PIONEER-HF
eligible cohort, and 33.1% (95% CI, 32.3-33.9) for the a
58 at matched one transplanted patient with all
eligible control candidates.
59 Eligible Covid-19 cases were non-hospitalized adult pati
60 Of the 180 participants (96.3% of the 187
eligible COVID-19 patients), 53.1% reported persistence
61 been near-uniform support for replacing the
eligible death denominator with CDC data, a source of co
62 th 3.52 fewer expected kidney donors per 100
eligible deaths than non-Gulf States.
63 the same communities, 10 791 (86%) of 12 489
eligible enumerated residents not previously enrolled in
64 For 247 of 266
eligible episodes all mandatory items required for the '
65 Of the 594
eligible eyes, the number with BCVA of 20/200 or worse a
66 Eligible facilities were pair-matched and randomly assig
67 te ovarian failure risk were developed using
eligible female US and Canadian participants in the Chil
68 Of 177
eligible firearm injury survivors, 100 were successfully
69 Responses from 347 of 808
eligible first- and second-year adult nephrology fellows
70 how WIC authorization affected sales of WIC-
eligible foods in 8 DVS pilot stores, compared with 8 ma
71 the adolescent MenACWY programme in children
eligible for 4CMenB but not MenACWY.
72 -cohorts that were fully-eligible and partly-
eligible for 4CMenB, respectively.
73 and/or skin prick testing, 238 (10.4%) were
eligible for a DBPCFC.
74 ria have expanded the number of CIS patients
eligible for a diagnosis of MS at the onset of the disea
75 A multistate cohort of ADAP clients
eligible for ADAP-funded QHPs were studied (2014-2015).
76 ember 2009 and June 2013, 180 HNSCC patients
eligible for adjuvant chemotherapy after surgery with cu
77 ere 1,007 healthy adults aged 40 to 74 years
eligible for an NHS Health Check.
78 Thirty-four studies with 1604 patients were
eligible for analyses.
79 e identified, and 243 OPSs and 153 RCTs were
eligible for analysis after exclusion based on pre-decid
80 ousand two hundred seventy-six patients were
eligible for analysis of baseline characteristics and 32
81 BTS or ES; 115 (SBTS n = 56, ES n = 59) were
eligible for analysis, while 20 participants were exclud
82 Of 180 329 TB cases, 126 431 (70%) were
eligible for analysis, with 359 (0.28%) of eligible case
83 r who initiated ART at a programme site were
eligible for analysis.
84 341 charts reviewed, 251 (74%) patients were
eligible for analysis.
85 rotection among low-income surgical patients
eligible for both cost-sharing and premium subsidies, bu
86 HIV, and more uninsured patients or patients
eligible for both Medicare and Medicaid).
87 he patients with sinus venosus defects to be
eligible for catheter closure.
88 One-third of patients
eligible for cholecystectomy fulfil criteria for FD/IBS.
89 Low-income patients
eligible for cost-sharing and premium subsidies in the M
90 ics and were >=18 years old at delivery were
eligible for endpoint assessment.
91 nted by computer tomography angiography were
eligible for enrollment.
92 s that were screened, 2,007 were molecularly
eligible for entry into the trial, and 302 entered the t
93 CRSwNP and on the identification of patients
eligible for extended surgery and possibly biologics in
94 Of 1184 articles screened, 7 studies were
eligible for final inclusion (n = 941).
95 inical study, 24 in vivo-in vitro pairs were
eligible for further analysis, with 4 having been reject
96 Of 12 769 individuals who were
eligible for HIV testing, 12 407 (97.2%) accepted testin
97 Fourteen randomized clinical trials were
eligible for inclusion (96 158 participants), of which 1
98 women born in Denmark from 1962 to 1971 were
eligible for inclusion and followed from age 15 to 45 ye
99 There were 210 patients
eligible for inclusion for analysis.
100 Trials were
eligible for inclusion if published between 2008 and 201
101 Studies were
eligible for inclusion if they assessed the potential di
102 Women were
eligible for inclusion if they had a gestational age of
103 Adolescents were
eligible for inclusion if they were living with HIV, reg
104 rperium over a three month study period were
eligible for inclusion in our study.
105 independently reviewed, leaving 60 articles
eligible for inclusion in the review.
106 arcoma were enrolled in the study and deemed
eligible for inclusion in this cohort.
107 A total of 2,484 patients were
eligible for inclusion, of which 1,847 had 1-year follow
108 2659 papers screened, 37 unique studies were
eligible for inclusion, reported in 38 publications.
109 ation without severe congenital defects were
eligible for inclusion.
110 8 papers reporting on 56 unique studies were
eligible for inclusion.
111 between December 2014 and December 2017 were
eligible for inclusion.
112 015 without prior comorbidity diagnoses were
eligible for inclusion.
113 dentifying 103 data papers, of which 81 were
eligible for inclusion.
114 ified 131 relevant studies, of which 19 were
eligible for inclusion: 12 examining cognitive behaviour
115 ged >60 years) with newly diagnosed AML, not
eligible for intensive chemotherapy; secondary AML (prog
116 017, patients >= 18 years old and considered
eligible for intensive therapy were randomly assigned up
117 A total of 293 patients were
eligible for intention-to-treat analysis: 157 in the con
118 AIS patients
eligible for intravenous r-tPA therapy were recruited.
119 ervention n = 6,877, control n = 6,335) were
eligible for ITT analysis.
120 subsidies, but not in middle-income patients
eligible for only premium subsidies.
121 ion in patients with atrial fibrillation not
eligible for oral anticoagulation therapy.
122 were excluded, leaving 893 pseudophakic eyes
eligible for outcome analysis.
123 teristics and clinical outcomes for patients
eligible for PIONEER-HF only modestly differ when compar
124 d 43 spontaneous or elective abortions) were
eligible for post-pregnancy viral load trajectory analys
125 oratory or clinical evidence of COVID-19 and
eligible for propensity score matching.
126 Adults (aged >=18 years) were
eligible for randomization on day 5 (+/-1 d) of microbio
127 Study designs
eligible for review included observational cohort and ca
128 lity or the need for semen donation who were
eligible for standard bolus intra-uterine insemination (
129 lation, among whom 13-28 million adults were
eligible for statin initiation.
130 18 guideline identified fewer younger adults
eligible for statin therapy at the time of their MI than
131 s without a history of ASCVD or T2D who were
eligible for statin treatment initiation.
132 patients with classic Hodgkin lymphoma were
eligible for study enrolment if they were 60 years or ol
133 10 had undetectable viral loads but are not
eligible for SVR(12) , and 7 remain on treatment.
134 nths but who reported a recent risk were all
eligible for testing.
135 Patients were
eligible for the biliary tract cancer cohort if they wer
136 223)Ra and at treatment discontinuation were
eligible for the study.
137 ectable hCCA between 2004 and 2016, who were
eligible for the treatment protocol, were prospectively
138 between December 2017 and January 2019 were
eligible for this study.
139 phoma), were between 16 and 70 years of age,
eligible for transplantation with a Karnofsky score of a
140 tnam, we assessed the proportion of patients
eligible for treatment using the national guidelines bas
141 umulative HCV treatment uptake in those ever
eligible for treatment was 91% (336/371).
142 ion for the Study of Liver Diseases who were
eligible for treatment with TACE were enrolled.
143 ve men were screened to identify 50 patients
eligible for treatment.
144 These groups were
eligible for US government benefits to help them resettl
145 Eligible histological subgroups included diffuse large B
146 Among 1454 treatment-
eligible HIV-infected MSM and 1939 PWID, older age (adju
147 Records were
eligible if they included any instrument developed, test
148 of randomized controlled trials (RCTs) were
eligible if they measured the effect of dietary patterns
149 lated coronavirus disease 2019 patients were
eligible if they underwent a CT pulmonary angiography, a
150 Patients were
eligible if they were aged 50 years or older, had been t
151 Children were
eligible if they were born in a KPNC or contracting hosp
152 Instruments were
eligible if they were originally developed to measure th
153 ge, sex, histology, or stage were considered
eligible,
including those in active treatment and clinic
154 2017, 55 enumeration area clusters had 1118
eligible index cases that led to 342 interventions cover
155 to evaluate adherence to this pattern among
eligible individuals (n = 48,246) from 1986 through 2012
156 evel (i.e., going house to house to identify
eligible individuals).
157 The psychometric quality of
eligible instruments was evaluated using a newly develop
158 Eligible men were aged 18 years or older with female par
159 Of those screened, 300 were
eligible (
mITT population); 290 patients underwent decom
160 daratumumab (D) to RVd (D-RVd) in transplant-
eligible NDMM patients was evaluated.
161 However, it is unclear how memory-
eligible neurons react during learning to encode trace f
162 Eligible newly recruited individuals must have received
163 erty level (FPL)] and middle-income patients
eligible only for premium subsidies (251%-400% FPL) were
164 83%) of 1722 pediatric patients were vaccine-
eligible;
only 68 (5%) of 1361 were known to be vaccinat
165 Eligible participants from the ATLAS trial, from both th
166 Eligible participants had information about self-reporte
167 7320 (61.9%)
eligible participants had physical multimorbidity in Chi
168 Eligible participants included adults with PA and parent
169 o were eligible registered, and 71.5% of all
eligible participants registered on the spot.
170 Eligible participants were adults (18-85 years) who pres
171 Eligible participants were adults (aged >=18 years) newl
172 Eligible participants were adults (aged >=18 years) with
173 of women in households continued until 20-30
eligible participants were identified per site.
174 Eligible participants were mothers or female primary car
175 After a 4-week observation period,
eligible participants were randomised using an interacti
176 Eligible participants were randomized to receive oseltam
177 Eligible participants were women aged 18 years or older
178 Eligible participants were women with chronic pelvic pai
179 The most common adverse events, in 329
eligible participants who began treatment, were neutrope
180 deline Group clinical guidelines (N = 10,522
eligible participants).
181 Of 1,487 potentially
eligible participants, 203 were randomly assigned to a s
182 re a total of 585 HCV initiations among 1130
eligible participants.
183 Of 1,239
eligible patients (61 +/- 18 years, 80% men), 1,072 (86%
184 ; mean [SD] PSA level, 4.9 [2.1] ng/mL), 443
eligible patients (93%) were included in the primary ana
185 Eligible patients (aged >=18 years) had deleterious germ
186 Eligible patients (aged >=18 years) had histologically c
187 A total of 111
eligible patients (n(implants) = 501) were assessed.
188 nsplantation (ASCT) is a standard of care in
eligible patients and results in immune effects beyond c
189 ional differences exist in the proportion of
eligible patients discharged on GDMT, which was strongly
190 Eligible patients for part A (dose-confirmation phase) o
191 Eligible patients from the ZETA trial were divided into
192 Eligible patients had a haematological malignancy (leuka
193 Eligible patients had FIP1L1-PDGFRA-negative HES, experi
194 Eligible patients had MBC with measurable disease and ge
195 Eligible patients had metastatic renal cell carcinoma (R
196 Eligible patients had multiple myeloma and had relapsed
197 Eligible patients had previously untreated acute myeloid
198 Eligible patients had submassive or massive pulmonary em
199 In Myeloma IX, transplant-
eligible patients randomly assigned to cyclophosphamide,
200 Eligible patients received a single intravesical 75 mL d
201 mly assigned (intention to treat), and 1,068
eligible patients started their allocated treatment (arm
202 Eligible patients tested positive for severe acute respi
203 additional 1.7 (P<0.01), and the percent of
eligible patients treated with alteplase increased by 8%
204 Eligible patients were 18-70 years, had acute myeloid le
205 Eligible patients were 50 years of age or older with wel
206 Eligible patients were 60 years or older, already receiv
207 Eligible patients were 80 years old or older when they u
208 Eligible patients were aged >=50 years.
209 In both studies,
eligible patients were aged 18 years or older and had an
210 Eligible patients were aged 18 years or older with a dis
211 Eligible patients were aged 18 years or older with an Ea
212 Eligible patients were aged 18 years or older with histo
213 Eligible patients were aged 18 years or older, had untre
214 Eligible patients were aged 18 years or older, were hosp
215 Eligible patients were aged 18-80 years with stage IV me
216 Eligible patients were aged 2-65 years, with acute, unco
217 Eligible patients were aged 21-85 years and had had eith
218 106 540/1 071 943 (9.9%)
eligible patients were diagnosed with comorbidity.
219 Between July 7, 2014, and Oct 1, 2018, 81
eligible patients were enrolled and randomly assigned to
220 Between June 5, 2013, and Jan 10, 2019, 58
eligible patients were enrolled to the study: 29 patient
221 Eligible patients were postmenopausal women with early-s
222 Eligible patients were pseudophakic, with mild/moderate
223 Eligible patients were randomly assigned (1:1) to receiv
224 Eligible patients were randomly assigned (1:1) using per
225 Eligible patients were those with operable, node-positiv
226 Eligible patients were unsuitable or refractory to trans
227 were done on intention-to-treat basis among
eligible patients who were evaluable for response.
228 remaining 109 clinics, we identified 13 657
eligible patients who were sent an introductory letter w
229 ute care unit (VACU) in the home setting for
eligible patients with COVID-19.
230 done in Canada, Spain, and the USA, in which
eligible patients with multiple myeloma had received 3 o
231 itional injections of ranibizumab 0.5 mg for
eligible patients with neovascular age-related macular d
232 iver transplantation should be encouraged in
eligible patients with recurrence.
233 s (with a 63% refusal rate among potentially
eligible patients); these factors may limit generalizabi
234 Eligible patients, 16 to 40 years of age with geneticall
235 Of the 333
eligible patients, 165 were randomly assigned to receive
236 Of 237
eligible patients, 199 patients received a single IVIg c
237 Results: Of 41
eligible patients, 24 patients had recurrent disease at
238 Among hospitals with >=100
eligible patients, UAT proportions ranged from 0% to 69%
239 double-lung transplantation is an option for
eligible patients.
240 l included a reasonable percentage of 33% of
eligible patients.
241 photographs were available for 615/862 (71%)
eligible patients.
242 sen cluster crossed over to providing RFP to
eligible patients.
243 hest risk quintile cared for 52.0% of dually
eligible patients; those in the 3 middle risk quintiles,
244 Approximately 95% of currently vaccine-
eligible pediatric travelers were unvaccinated, and anti
245 Furthermore, many screen-
eligible people remain unscreened.
246 Of 2,382 potentially
eligible people, 637 from 5 intervention clusters and 1,
247 There were 476
eligible PICU admissions, for whom 1,218 surveys were co
248 s did not improve the chewing ability in the
eligible population.
249 ew policy improved of chewing ability in the
eligible population.
250 y to ensure newly arrived refugees and other
eligible populations receive recommended health screenin
251 reening proportions among refugees and other
eligible populations to assess the domestic medical exam
252 population-based study of 1,753,865 Medicaid-
eligible pregnancies between January 2000 and December 2
253 NSQIP-
eligible procedures were queried within 90 days followin
254 assessment, and risk assessment for bias of
eligible publications were performed along recommended g
255 ed individual participant data from 14 of 20
eligible randomised controlled trials (8278 [79%] of 10
256 systematic search was performed to identify
eligible randomized clinical trials (RCTs) reporting on
257 The systematic review identified 114
eligible randomized trials of antibiotic prophylaxis.
258 A total of 105
eligible RCTs were included.
259 From 4229 studies screened, we identified 86
eligible RCTs; 52, with data from over 70 000 patients,
260 pleted responses were obtained from 62 of 87
eligible recipients (71.2% response rate).
261 randomised with 106 pairs transplanted into
eligible recipients.
262 The study period included 133 million
eligible records with 61,071 cases of incident RRD among
263 of medical/healthcare participants who were
eligible registered, and 71.5% of all eligible participa
264 Of 717
eligible relatives (598 first-degree and 119 second-degr
265 We randomized 823 NHs, housing 50,012
eligible residents, to aTIV or TIV.
266 Eligible studies had to be published between 2000 and 20
267 Eligible studies investigated the association of ART, CD
268 We identified 7
eligible studies published between 2008 and 2019, provid
269 Investigators of the
eligible studies published from 1990 to 2018 were invite
270 Eligible studies reported at least 1 of the following ou
271 Eligible studies reported peer-reviewed qualitative rese
272 Eligible studies were included in meta-analyses.
273 Data from
eligible studies were pooled using standardised methodol
274 The systematic review identified 19
eligible studies.
275 acted data, and assessed the risk of bias of
eligible studies.
276 variables were requested from authors of all
eligible studies.
277 Eligible subjects were randomly allocated to either rece
278 Following a washout period, 99
eligible subjects were randomly assigned to one of the f
279 Eligible subjects were tested every 3 months with color
280 s (5185 ERP and 4307 controls) underwent ERP
eligible surgery during the study period.
281 e case-control analysis was performed on all
eligible surgical patients between 2014-2017 after ERP i
282 31, 2016, and 8,172 of these underwent NSQIP-
eligible surgical procedures.
283 A total of 81% (26 of 32) of
eligible technologists completed the survey.
284 All studies were
eligible that investigated the impact of fluid overload
285 Of these, 32 were
eligible to be included in the study.
286 Individuals (aged >=2 years) were
eligible to participate if they were confirmed HIV-serop
287 t children (89.3%) assessed in our study and
eligible to participate in the mass dengue vaccination c
288 All patients were
eligible to receive aflibercept as needed at weeks 4, 8,
289 rades II to IV steroid-refractory aGVHD were
eligible to receive ruxolitinib orally, starting at 5 mg
290 tients with stage IV measurable disease were
eligible to receive VI (vincristine, 1.5 mg/m(2) per day
291 t trialists, we were able to anticipate when
eligible trial results would emerge, and we developed an
292 We identified three
eligible trials and were able to obtain updated results
293 Of 326 981
eligible veterans (mean [SD] age, 81.1 [4.1] years; 97%
294 ed a retrospective cohort of 34 775 Medicare-
eligible veterans with group 2/3 PH by linking national
295 Among all
eligible visits, 3.5% (18,682) were followed by a suicid
296 Eligible volunteers were HIV-uninfected individuals aged
297 to 10 and June 11 to 13, of 5,612 and 5,818
eligible voters, respectively, with an embedded experime
298 tic syndrome or acute myeloid leukaemia were
eligible without additional restriction.
299 randomized controlled noninferiority trial,
eligible WLHIV were ages 18-40, not pregnant or desiring
300 Among
eligible women (N = 577), 189 (33%) had undergone RS tes